文献速递医院感染防控新发突发、热带与寄生虫病

乌干达和尼泊尔婴儿DTwP疫苗免疫程序优化:两项开放标签非劣效随机对照试验

Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials.
PubMed 文献 · Lancet Infect Dis · 2026-03-19

在乌干达和尼泊尔开展的两项平行、开放标签、非劣效随机对照试验,将956名42-50日龄健康婴儿按4:4:4:3:3随机分配至五种DTwP-Hib-HepB疫苗接种程序。主要结局为加强免疫前百日咳抗原IgG抗体应答。结果显示,两剂次程序(6和14周或2和4月龄)除尼泊尔FHA外未达到非劣效标准;延迟三剂次程序产生与WHO程序相似或更高的应答,但WHO程序在3月龄时对多数百日咳抗原抗体应答更高。结论支持WHO程序在高百日咳负担地区为优选方案。

要点

  • 两剂次DTwP程序(6和14周或2和4月龄)加强前百日咳抗体未达非劣效标准。
  • 延迟三剂次程序(2、3、4月龄或2、4、6月龄)应答与WHO程序相似或更高。
  • WHO程序在3月龄时对多数百日咳抗原抗体应答最高,高负担地区应优先采用。

核心结论

  • WHO DTP程序在高百日咳负担地区为优选方案,因其在婴儿最脆弱的前3个月产生最高抗体应答。
  • 延迟三剂次程序可在低风险环境及有母体免疫规划的场景中考虑,但早期婴儿保护应指导政策决策。

研究设计与样本

  • 在乌干达和尼泊尔开展的两项平行、开放标签、非劣效随机对照试验,共纳入956名42-50日龄健康婴儿。
  • 婴儿按4:4:4:3:3比例随机分配至五种DTwP-Hib-HepB接种程序:WHO程序(6、10、14周)、两剂次程序(6和14周或2和4月龄)、延迟三剂次程序(2、3、4月龄或2、4、6月龄)。
  • 主要结局为加强免疫前针对百日咳抗原(百日咳毒素、丝状血凝素、百日咳杆菌粘附素、菌毛2和3)的IgG抗体应答,在符合方案人群中分析。

主要发现

  • 延迟三剂次程序(2、3、4月龄及2、4、6月龄)基础免疫后及加强前应答与WHO程序相似或更高。
  • WHO程序在3月龄时对 all 百日咳抗原(尼泊尔FHA除外)抗体应答高于延迟程序。

关键数值与推荐

  • 主要终点非劣效界值:两剂次与WHO程序几何均值比(GMR)的界值为WHO组几何均值浓度标准差的35%,若GMR的95%CI下限超过该界值则判定非劣效。

临床怎么用

  • 在高百日咳负担地区,应优先采用WHO推荐的6、10、14周DTwP程序以保障早期婴儿保护。
  • 低风险地区或已有母体免疫规划的场景可考虑延迟三剂次程序,但需权衡早期保护。

局限性

  • 两剂次程序未达非劣效标准,延迟三剂次程序为探索性分析。
  • 结果主要基于符合方案人群,可能受依从性影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Few data are available comparing the WHO diphtheria-tetanus-pertussis (DTP)-containing vaccine schedule with reduced-dose or delayed three-dose schedules in infants. We aimed to identify an alternative schedule that is non-inferior or superior to the WHO schedule in maintaining early pertussis antibody levels before booster, while creating space for integration of new vaccines. METHODS: In two parallel, open-label, randomised, non-inferiority trials in Uganda and Nepal, healthy infants aged 42-50 days were randomised in a 4:4:4:3:3 ratio via an online system to five diphtheria-tetanus-whole-cell pertussis-Haemophilus influenzae type b-hepatitis B (DTwP-Hib-HepB) vaccination schedules (WHO schedule [ages 6, 10, and 14 weeks]; reduced two-dose schedules at ages 6 and 14 weeks or ages 2 and 4 months; or delayed three-dose schedules at ages 2, 3, and 4 months or ages 2, 4, and 6 months), using site-stratified block randomisation with a block size of 18. The primary outcome was the pre-booster IgG antibody response against pertussis antigens (pertussis toxin; filamentous haemagglutinin [FHA]; pertactin; fimbriae 2 and 3 [Fim 2 and 3]). Antibody responses during and 1 month after the primary series were assessed as secondary endpoints. The two-dose schedules were compared with the WHO schedule as primary analyses, and the exploratory analyses were to compare delayed three-dose schedules with the WHO schedule. All these analyses were conducted in the per-protocol population. For the primary endpoint, non-inferiority margins for geometric mean ratios (GMRs) between two-dose and WHO schedules were calculated for each pertussis antigen separately as 35% of the standard deviation of the geometric mean concentrations of the WHO group, and non-inferiority was concluded if the lower bound of the 95% CI of the GMR exceeded the non-inferiority margin. A non-inferiority margin of 0·67 was used for all other non-inferiority comparisons. The trials were registered with ISRCTN (Uganda [ISRCTN60356654] and Nepal [ISRCTN12240140]) and are complete. FINDINGS: Between Oct 1, 2021, and July 12, 2022 (Uganda) and Dec 5, 2021, and Feb 26, 2023 (Nepal), 956 infants were recruited per country and randomly allocated across the five study groups; pre-booster analyses were conducted in 876 participants in Uganda and 851 participants in Nepal. Two-dose schedules at ages 6 and 14 weeks and ages 2 and 4 months did not meet non-inferiority criteria for pertussis antibodies pre-booster, except FHA (non-inferiority margin 0·59) in Nepal (6 and 14 weeks GMR 0·83 [95% CI 0·61-1·13]; 2 and 4 months 1·20 [0·88-1·64]). Delayed three-dose schedules at ages 2, 3, and 4 months and ages 2, 4, and 6 months produced similar or higher post-primary series and pre-booster responses compared with the WHO schedule, but the WHO schedule achieved higher antibody responses against all pertussis antigens, except FHA in Nepal, at age 3 months. INTERPRETATION: The WHO DTP schedule is the preferred schedule in high-pertussis-burden settings, as it elicits the greatest antibody responses in the first 3 months of life when infants are particularly vulnerable. Although delayed three-dose schedules may be considered in low-risk contexts and in settings with maternal immunisation programmes, early infant protection should guide policy decisions. FUNDING: Gates Foundation.

来源:Lancet Infect Dis,查看原文。版权归原作者所有。

引用

  1. Bijukchhe SM, Marchevsky NG, Kibengo F, et al. Optimising DTwP-containing vaccine infant immunisation schedules in Uganda and Nepal (OptImms): two open-label, non-inferiority, randomised controlled trials. Lancet Infect Dis. 2026. PMID: 41865748. doi:10.1016/S1473-3099(26)00053-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。